High-throughput crystallization:: polymorphs, salts, co-crystals and solvates of phan-naceutical solids

被引:551
作者
Monissette, SL
Almarsson, Ö
Peterson, ML
Remenar, JF
Read, MJ
Lemmo, AV
Ellis, S
Cima, MJ
Gardner, CR
机构
[1] TransForm Pharmaceut Inc, Lexington, MA 02421 USA
[2] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA
关键词
high-throughput; crystallization; polymorph; solvate; salt; co-crystal;
D O I
10.1016/j.addr.2003.10.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The concepts of high-throughput (HT) screening and combinatorial synthesis have been integrated into the pharmaceutical discovery process, but are not yet commonplace in the pharmaceutical development arena. Emerging strategies to speed pharmaceutical development and capture solid form diversity of pharmaceutical substances have resulted in the emergence of HT crystallization technologies. The primary type of diversity often refers to polymorphs, which are different crystal forms of the same chemical composition. However, diverse salt forms, co-crystals, hydrates and solvates are also amenable to study in HT crystallization systems. The impact of form diversity encompasses issues of stability and bioavailability, as well as development considerations such as process definition, formulation design, patent protection and regulatory control. This review highlights the opportunities and challenges of HT crystallization technologies as they apply to pharmaceutical research and development. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:275 / 300
页数:26
相关论文
共 104 条
[51]   Polymorph control of sulfathiazole in supercritical CO2 [J].
Kordikowski, A ;
Shekunov, T ;
York, P .
PHARMACEUTICAL RESEARCH, 2001, 18 (05) :682-688
[52]   The effect of solvent on crystal growth and morphology [J].
Lahav, M ;
Leiserowitz, L .
CHEMICAL ENGINEERING SCIENCE, 2001, 56 (07) :2245-2253
[53]   The use of polymer heteronuclei for crystalline polymorph selection [J].
Lang, MD ;
Grzesiak, AL ;
Matzger, AJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (50) :14834-14835
[54]   Form IV of carbamazepine [J].
Lang, MD ;
Kampf, JW ;
Matzger, AJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (04) :1186-1190
[55]  
Leiserowitz L, 2002, ABSTR PAP AM CHEM S, V223, pU628
[56]   Crystal structure prediction of diastereomeric salts: A step toward rationalization of racemate resolution [J].
Leusen, FJJ .
CRYSTAL GROWTH & DESIGN, 2003, 3 (02) :189-192
[57]   Drug-like properties and the causes of poor solubility and poor permeability [J].
Lipinski, CA .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) :235-249
[58]   A test of crystal structure prediction of small organic molecules [J].
Lommerse, JPM ;
Motherwell, WDS ;
Ammon, HL ;
Dunitz, JD ;
Gavezzotti, A ;
Hofmann, DWM ;
Leusen, FJJ ;
Mooij, WTM ;
Price, SL ;
Schweizer, B ;
Schmidt, MU ;
van Eijck, BP ;
Verwer, P ;
Williams, DE .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE CRYSTAL ENGINEERING AND MATERIALS, 2000, 56 (04) :697-714
[59]   Control of crystal habit and size of cefmatilen hydrochloride hydrate with a habit modifier [J].
Masui, Y ;
Kitaura, Y ;
Kobayashi, T ;
Goto, Y ;
Ando, S ;
Okuyama, A ;
Takahashi, H .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2003, 7 (03) :334-338
[60]  
McCrone W.C., 1965, PHYS CHEM ORGANIC SO, V2